Pharmacology terms describe exposure, action, metabolism, and interpretation.
Dictionary / Pharmacology
Pharmacokinetics
How a compound is absorbed, distributed, metabolized, and eliminated.
Pharmacologyterm category
0related public pages
editorial navigationdefinition status
draftreview status
21exact evidence rows
16exact source links
0nearby evidence rows
0nearby source links
0do-not-confuse links
0entity links
This page is a dictionary definition and navigation aid. Exact evidence rows below come from approved workbench claims; broader claims and citations live on the related source-backed pages.
Dictionary Reader Map
Use the definition as a doorway, not a conclusion.
Pharmacokinetics explains vocabulary used across the cannabinoid encyclopedia. The definition orients the reader; exact rows and related pages carry the source-backed claims.
16 direct sources linked to approved workbench claims. PubMed 39528623
0 nearby evidence rows and 0 nearby source links.
Aliases help readers find the same concept without changing the evidence standard.
Plain-Language Definition
What it means here
Pharmacokinetics is used in this encyclopedia as a pharmacology term. How a compound is absorbed, distributed, metabolized, and eliminated.
Pharmacology terms describe what happens to a compound, what it does in a model, or how dose, route, target, and metabolism change interpretation.
No common aliases are listed for this term yet.
Evidence Guardrail
How to read it without overreaching
Read this term as part of the encyclopedia. The definition orients the reader, while source-backed pages carry the claims and citations.
Evidence Lens
What this term can currently point to
Direct approved claim rows linked to this dictionary term. PubMed 39528623
Distinct source records under those exact rows. PubMed 39528623
Source-backed public pages where this vocabulary is likely useful.
Evidence rows available on those related public pages.
Exact rows are direct evidence links. Use them first, then use related pages to understand the broader research context.
Source Path
How to move from this definition to research
- Read the definition.Use it to understand the vocabulary in plain English.
- Check exact rows.When direct rows exist, open the linked PubMed or DOI record. PubMed 39528623
- Open related pages.Use nearby pages for broader source-backed context.
- Keep the boundary.Pharmacology context depends on dose, route, product, model, and endpoint.
Exact Evidence Rows
Approved source-backed rows linked to this term
21 exact rows
No matching evidence rows.
Evidence Group
Preliminary Human
1 exact row / 1 source
Evidence row 28 / uses term
CBD studied for Anxiety-related outcomes.
preliminary human / very_low confidence.
Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. PubMed 38797087
Claim or source metadata contains an explicit term marker.
Evidence Group
Insufficient
9 exact rows / 8 sources
Evidence row 100 / uses term
Cannabinoids studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding. PubMed 35903331
Claim or source metadata contains an explicit term marker.
Evidence row 177 / uses term
THC studied for pregnancy, lactation, pediatric, adolescent, or developmental contexts.
insufficient / very_low confidence.
Cannabis use during pregnancy: Pharmacokinetics and effects on child development. PubMed 28847562
Claim or source metadata contains an explicit term marker.
Evidence row 196 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 198 / uses term
CBD studied for safety, adverse-event, impairment, or formulation-specific concerns.
insufficient / very_low confidence.
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. PubMed 31802404
Claim or source metadata contains an explicit term marker.
Evidence row 273 / uses term
THC studied for Cannabinoids and immune modulation research outcomes.
insufficient / very_low confidence.
Pharmacokinetics and pharmacodynamics of cannabinoids. PubMed 12648025
Claim or source metadata contains an explicit term marker.
Evidence row 281 / uses term
CBD studied for receptor, target, or pharmacology mechanisms.
insufficient / very_low confidence.
Pharmacokinetics of Non-Psychotropic Phytocannabinoids. PubMed 40006604
Claim or source metadata contains an explicit term marker.
Evidence row 661 / uses term
CBC modulates receptor, transporter, target, metabolic, or pharmacology mechanisms.
insufficient / very_low confidence.
Pharmacokinetics of Non-Psychotropic Phytocannabinoids. PubMed 40006604
Claim or source metadata contains an explicit term marker.
Evidence row 838 / uses term
Cannabinoids modulates CB1.
insufficient / very_low confidence.
Computational Analysis of Dipyrone Metabolite 4-Aminoantipyrine As A Cannabinoid Receptor 1 Agonist. PubMed 31490743
Claim or source metadata contains an explicit term marker.
Evidence row 1195 / uses term
SEA studied for SEA biology, metabolism, physiology, or safety-relevant mechanisms.
insufficient / very_low confidence.
Lipidomic Analysis of Endocannabinoid Signaling: Targeted Metabolite Identification and Quantification. PubMed 26839710
Claim or source metadata contains an explicit term marker.
Evidence Group
Preclinical
5 exact rows / 3 sources
Evidence row 10 / uses term
CBN increases Total sleep time.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence row 11 / uses term
CBN increases NREM sleep.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence row 12 / uses term
CBN increases REM sleep.
preclinical / moderate confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence row 353 / uses term
HHC studied for safety, risk, adverse-event, or formulation-specific concerns.
preclinical / very_low confidence.
Hexahydrocannabinol: pharmacokinetics, systemic toxicity, and acute behavioral effects in Wistar rats. PubMed 40643195
Claim or source metadata contains an explicit term marker.
Evidence row 974 / uses term
Cannabinoids modulates TRPV1.
preclinical / very_low confidence.
The analgesic paracetamol metabolite AM404 acts peripherally to directly inhibit sodium channels. PubMed 40465624
Claim or source metadata contains an explicit term marker.
Evidence Group
Mechanistic or Pharmacological
6 exact rows / 6 sources
Evidence row 13 / uses term
CBN modulates sleep architecture through 11-hydroxy-CBN activity in rats.
mechanistic or pharmacological / low confidence.
A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats PubMed 39528623
Claim or source metadata contains an explicit term marker.
Evidence row 47 / uses term
CBD interacts with drug or class drug-interaction mechanisms or safety-relevant outcomes.
mechanistic or pharmacological / very_low confidence.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects. PubMed 30374683
Claim or source metadata contains an explicit term marker.
Evidence row 165 / uses term
CBDA studied for safety, adverse-event, impairment, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs. PubMed 41822224
Claim or source metadata contains an explicit term marker.
Evidence row 560 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. PubMed 36272108
Claim or source metadata contains an explicit term marker.
Evidence row 562 / uses term
CBG studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation. PubMed 35246858
Claim or source metadata contains an explicit term marker.
Evidence row 651 / uses term
CBC studied for safety, tolerability, adverse-event, impairment, toxicity, or formulation-specific concerns.
mechanistic or pharmacological / very_low confidence.
Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs. PubMed 33134364
Claim or source metadata contains an explicit term marker.
Source-Backed Connections
Related pages in the current encyclopedia
No source-backed public page is linked to this term in the current launch set yet. Start with the evidence method, then add sources as the term page matures.
Nearby Terms